Anti-COVID-19 Activity of FDA Approved Drugs through RNA G-quadruplex Binding
Roy, S. S.; Sharma, S.; Rizvi, Z. A.; Sinha, D.; Gupta, D.; Rophina, M.; Sehgal, P.; Sadhu, S.; Tripathy, M. R.; Samal, S.; Maiti, S.; Scaria, V.; Sivasubbu, S.; Awasthi, A.; Harshan, K.; Jain, S.; Chowdhury, S.
Show abstract
The COVID-19 pandemic caused by SARS-CoV-2 has caused millions of infections and deaths worldwide. Limited treatment options and the threat from emerging variants underline the need for novel and widely accessible therapeutics. G-quadruplexes (G4s) are nucleic acid secondary structures known to affect many cellular processes including viral replication and transcription. We identified heretofore not reported G4s with remarkably low mutation frequency across >5 million SARS-CoV-2 genomes. The G4 structure was targeted using FDA-approved drugs that can bind G4s - Chlorpromazine (CPZ) and Prochlorperazine (PCZ). We found significant inhibition in lung pathology and lung viral load of SARS-CoV-2 challenged hamsters when treated with CPZ, PCZ that was comparable to the widely used antiviral drug Remdesivir. In support, in vitro G4 binding, inhibition of reverse transcription from RNA isolated from COVID-infected humans, and attenuated viral replication and infectivity in Vero cell cultures were clear in case of both CPZ/PCZ. Apart from the wide accessibility of CPZ/PCZ, targeting relatively invariant nucleic acid structures poses an attractive strategy against fast mutating viruses like SARS-CoV-2.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting 97%
- The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo 96%
- Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 96%
Similar papers in this journal
- The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines 96%
- The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models 95%
- Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against Respiratory Syncytial Virus 95%
Similar papers in this journal
- Potential antiviral options against SARS-CoV-2 infection 96%
- ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection 95%
- Cell culture model system utilizing engineered A549 cells to express high levels of ACE2 and TMPRSS2 for investigating SARS-CoV-2 infection and antivirals 95%
Similar papers in this journal
- Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E 93%
- Genetic insertion of mouse Myxovirus-resistance gene 1 increases innate resistance against both high and low pathogenic avian influenza virus by significantly decreasing replication in chicken DF1 cell line 92%
- Chikungunya virus non-structural protein 2 (nsP2) inhibits RIG-I and TLR-mediated immune response 92%
Similar papers in this journal
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 95%
- In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication 95%
- Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.